Moderna (NASDAQ:MRNA) announced today a significant reduction in its research and development budget, sending shockwaves through the biotech industry and causing its stock to plummet. The company, known for its mRNA technology and COVID-19 vaccine, plans to cut $1.1 billion from its R&D spending by 2027 as it grapples with commercial setbacks and a shifting market landscape.
Moderna’s Strategic Shift and Pipeline Adjustments
In a move described as a “more selective and paced approach” to drug development, Moderna outlined plans to reduce its annual R&D spending from the current $4.8 billion to between $3.6 billion and $3.8 billion by 2027.
The company has discontinued five programs, including vaccines for endemic human coronaviruses and a pediatric RSV program, as well as several oncology and cardiovascular candidates. Notably, Moderna has abandoned plans for accelerated approval of its standalone flu vaccine, shifting focus to a flu-COVID combination shot.
Despite these cuts, Moderna maintains ambitious goals, aiming to secure 10 approvals over the next three years. However, the company has pushed back its break-even timeline to 2028, two years later than previously anticipated. This delay, coupled with regulatory hurdles for key prospects like the cancer therapy mRNA-4157, partnered with Merck & Co., has raised concerns about Moderna’s path to profitability.
Moderna Stock Drops Over 17%
The announcement triggered a sharp decline in Moderna’s stock price, which fell 17.62% to $65.50 as of 10:02 AM EDT.
This drop reflects investor concerns about the company’s future prospects and ability to diversify beyond its COVID-19 vaccine revenue stream. Moderna’s market capitalization has shrunk to $25.178 billion, with the stock experiencing significant underperformance compared to the broader market.
Moderna’s financial metrics paint a challenging picture, with a profit margin of -116.18% and a return on equity of -40.94%. The company reported $5.05 billion in trailing twelve-month revenue and holds $8.49 billion in cash, but faces pressure to achieve $6 billion in sales to break even by 2028.
Analyst recommendations remain mixed, with price targets ranging from $58.00 to $310.00, underscoring the uncertainty surrounding Moderna’s future performance.
***
Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.
This article was originally published on The Tokenist. Check out The Tokenist’s free newsletter, Five Minute Finance, for weekly analysis of the biggest trends in finance and technology.